Found 5 results
Filters: Author is M. Mao  [Clear All Filters]
W. Zeng, Liu, L., Tong, Y., Liu, H. M., Dai, L., and Mao, M., A66G and C524T polymorphisms of the methionine synthase reductase gene are associated with congenital heart defects in the Chinese Han population, vol. 10, pp. 2597-2605, 2011.
Berry RJ, Li Z, Erickson JD, Li S, et al. (1999). Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N. Engl. J. Med. 341: 1485-1490. PMid:10559448 Botto LD and Correa A (2003). Decreasing the burden of congenital heart anomalies: an epidemiologic evaluation of risk factors and survival. Prog. Pediatr. Cardiol. 18: 111-121. Botto LD, Khoury MJ, Mulinare J and Erickson JD (1996). Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 98: 911-917. PMid:8909485 Botto LD, Mulinare J and Erickson JD (2000). Occurrence of congenital heart defects in relation to maternal mulitivitamin use. Am. J. Epidemiol. 151: 878-884. PMid:10791560 Botto LD, Mulinare J and Erickson JD (2003). Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am. J. Med. Genet. A 121A: 95-101. PMid:12910485 Botto LD, Olney RS and Erickson JD (2004). Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am. J. Med. Genet. C. Semin. Med. Genet. 125C: 12-21. PMid:14755429 Brookes AJ (1999). The essence of SNPs. Gene 234: 177-186. Czeizel AE (1998). Periconceptional folic acid containing multivitamin supplementation. Eur. J. Obstet. Gynecol. Reprod. Biol. 78: 151-161. Czeizel AE and Dudás I (1992). Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327: 1832-1835. PMid:1307234 Czeizel AE, Dobo M and Vargha P (2004). Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res. A Clin. Mol. Teratol. 70: 853-861. PMid:15523663 Deng L, Elmore CL, Lawrance AK, Matthews RG, et al. (2008). Methionine synthase reductase deficiency results in adverse reproductive outcomes and congenital heart defects in mice. Mol. Genet. Metab. 94: 336-342. PMid:18413293    PMCid:3110750 Elmore CL, Wu X, Leclerc D, Watson ED, et al. (2007). Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol. Genet. Metab. 91: 85-97. PMid:17369066    PMCid:1973089 Fredriksen A, Meyer K, Ueland PM, Vollset SE, et al. (2007). Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum. Mutat. 28: 856-865. PMid:17436311 Gellekink H, den Heijer M, Heil SG and Blom HJ (2005). Genetic determinants of plasma total homocysteine. Semin. Vasc. Med. 5: 98-109. PMid:16047263 Hoffman JI and Kaplan S (2002). The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39: 1890-1900. Huhta JC, Linask K and Bailey L (2006). Recent advances in the prevention of congenital heart disease. Curr. Opin. Pediatr. 18: 484-489. PMid:16969161 Itikala PR, Watkins ML, Mulinare J, Moore CA, et al. (2001). Maternal multivitamin use and orofacial clefts in offspring. Teratology 63: 79-86.<79::AID-TERA1013>3.0.CO;2-3 Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, et al. (1999). Congenital heart defects and maternal derangement of homocysteine metabolism. J. Pediatr. 135: 773-774. Lai E (2001). Application of SNP technologies in medicine: lessons learned and future challenges. Genome Res. 11: 927- 929. PMid:11381021 Leclerc D, Odievre M, Wu Q, Wilson A, et al. (1999). Molecular cloning, expression and physical mapping of the human methionine synthase reductase gene. Gene 240: 75-88. Olteanu H and Banerjee R (2001). Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J. Biol. Chem. 276: 35558-35563. PMid:11466310 Rosenquist TH, Ratashak SA and Selhub J (1996). Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc. Natl. Acad. Sci. U. S. A. 93: 15227-15232. Shaw GM, Lu W, Zhu H, Yang W, et al. (2009). 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med. Genet. 10: 49. PMid:19493349    PMCid:2700092 Silaste ML, Rantala M, Sampi M, Alfthan G, et al. (2001). Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J. Nutr. 131: 2643-2647. PMid:11584084 Swanson DA, Liu ML, Baker PJ, Garrett L, et al. (2001). Targeted disruption of the methionine synthase gene in mice. Mol. Cell. Biol. 21: 1058-1065. PMid:11158293    PMCid:99560 Tennstedt C, Chaoui R, Korner H and Dietel M (1999). Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart 82: 34-39. PMid:10377306    PMCid:1729082 Tierney BJ, Ho T, Reedy MV and Brauer PR (2004). Homocysteine inhibits cardiac neural crest cell formation and morphogenesis in vivo. Dev. Dyn. 229: 63-73. PMid:14699578 van Beynum IM, Kouwenberg M, Kapusta L, den Heijer M, et al. (2006). MTRR 66A>G polymorphism in relation to congenital heart defects. Clin. Chem. Lab. Med. 44: 1317-1323. PMid:17087642 Verkleij-Hagoort AC, Verlinde M, Ursem NT, Lindemans J, et al. (2006). Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG 113: 1412-1418. Verkleij-Hagoort AC, van Driel LM, Lindemans J, Isaacs A, et al. (2008). Genetic and lifestyle factors related to the periconception vitamin B12 status and congenital heart defects: a dutch case-control study. Mol. Genet. Metab. 94: 112-119. PMid:18226574
L. Dong, Mao, M., Luo, R., Tong, Y., and Yu, D., Common ABCB1 polymorphisms associated with susceptibility to infantile spasms in the Chinese Han population, vol. 10, pp. 2569-2577, 2011.
Aronica E, Gorter JA, Ramkema M, Redeker S, et al. (2004). Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45: 441-451. PMid:15101825 Bobele GB and Bodensteiner JB (1994). The treatment of infantile spasms by child neurologists. J. Child. Neurol. 9: 432-435. PMid:7822738 Engel J Jr (2001). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42: 796-803. PMid:11422340 Fois A (2010). Infantile spasms: review of the literature and personal experience. Ital. J. Pediatr. 36: 15. PMid:20181122    PMCid:2829573 Frost JD Jr and Hrachovy RA (2005). Pathogenesis of infantile spasms: a model based on developmental desynchronization. J. Clin. Neurophysiol. 22: 25-36. PMid:15689710 Hancock E, Osborne JP and Milner P (2001). The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev. 23: 624-634. Hung CC, Jen TJ, Kao PJ, Lin MS, et al. (2007). Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8: 1151-1158. PMid:17924830 Ito M, Seki T and Takuma Y (2000). Current therapy for West syndrome in Japan. J. Child. Neurol. 15: 424-428. PMid:10868790 Kim YO, Kim MK, Woo YJ, Lee MC, et al. (2006). Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15: 67-72. PMid:16386926 Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, et al. (2007). A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. PMid:17185560 Komar AA (2007). Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8: 1075-1080. PMid:17716239 Koo B, Hwang PA and Logan WJ (1993). Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups. Neurology 43: 2322-2327. PMid:8232950 Kwan P, Baum L, Wong V, Ng PW, et al. (2007). Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 11: 112-117. Leschziner GD, Andrew T, Pirmohamed M and Johnson MR (2007). ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7: 154-179. PMid:16969364 Loscher W and Delanty N (2009). MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics 10: 711-713. PMid:19450121 Lux AL and Osborne JP (2004). A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 45: 1416-1428. PMid:15509243 Mikati MA, Lepejian GA and Holmes GL (2002). Medical treatment of patients with infantile spasms. Clin. Neuropharmacol. 25: 61-70. PMid:11981230 Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. PMid:3344216    PMCid:334765 Pellock JM (1990). The classification of childhood seizures and epilepsy syndromes. Neurol. Clin. 8: 619-632. PMid:2215459 Rantala H and Putkonen T (1999). Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 40: 286-289. PMid:10080506 Riikonen R (2004). Infantile spasms: therapy and outcome. J. Child. Neurol. 19: 401-404. PMid:15446386 Seo T, Ishitsu T, Ueda N, Nakada N, et al. (2006). ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7: 551-561. PMid:16753003 Siddiqui A, Kerb R, Weale ME, Brinkmann U, et al. (2003). Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348: 1442-1448. PMid:12686700 Tishler DM, Weinberg KI, Hinton DR, Barbaro N, et al. (1995). MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1-6. PMid:8001500 Tsao CY (2009). Current trends in the treatment of infantile spasms. Neuropsychiatr. Dis. Treat. 5: 289-299. PMid:19557123    PMCid:2695218 Tsuji T, Okumura A, Ozawa H, Ito M, et al. (2007). Current treatment of West syndrome in Japan. J. Child Neurol. 22: 560-564. PMid:17690062 Vahab SA, Sen S, Ravindran N, Mony S, et al. (2009). Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug. Metab. Pharmacokinet. 24: 255-260. PMid:19571437 Wheless JW, Clarke DF and Carpenter D (2005). Treatment of pediatric epilepsy: expert opinion, 2005. J. Child Neurol. 20 (Suppl 1): S1-56. PMid:16615562 Wheless JW, Clarke DF, Arzimanoglou A and Carpenter D (2007). Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 9: 353-412. PMid:18077226 Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, et al. (2009). Vigabatrin: 2008 update. Epilepsia 50: 163-173. PMid:19230067 Wong M and Trevathan E (2001). Infantile spasms. Pediatr. Neurol. 24: 89-98. Zimprich F, Sunder-Plassmann R, Stogmann E and Gleiss A (2004). Association of an ABCB1 gene haplotype with phamacoresistance in temporal lobe epilepsy. Neurology. 63: 1087-1089. PMid:15452305